These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

627 related articles for article (PubMed ID: 28408622)

  • 1. A Host-Dependent Prognostic Model for Elderly Patients with Diffuse Large B-Cell Lymphoma.
    Miura K; Konishi J; Miyake T; Makita M; Hojo A; Masaki Y; Uno M; Ozaki J; Yoshida C; Niiya D; Kitazume K; Maeda Y; Takizawa J; Sakai R; Yano T; Yamamoto K; Sunami K; Hiramatsu Y; Aoyama K; Tsujimura H; Murakami J; Hatta Y; Kanno M
    Oncologist; 2017 May; 22(5):554-560. PubMed ID: 28408622
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Impact of age group on febrile neutropenia risk assessment and management in patients with diffuse large B-cell lymphoma treated with R-CHOP regimens.
    Lugtenburg P; Silvestre AS; Rossi FG; Noens L; Krall W; Bendall K; Szabo Z; Jaeger U
    Clin Lymphoma Myeloma Leuk; 2012 Oct; 12(5):297-305. PubMed ID: 23040435
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Rituximab-dose-dense chemotherapy with or without high-dose chemotherapy plus autologous stem-cell transplantation in high-risk diffuse large B-cell lymphoma (DLCL04): final results of a multicentre, open-label, randomised, controlled, phase 3 study.
    Chiappella A; Martelli M; Angelucci E; Brusamolino E; Evangelista A; Carella AM; Stelitano C; Rossi G; Balzarotti M; Merli F; Gaidano G; Pavone V; Rigacci L; Zaja F; D'Arco A; Cascavilla N; Russo E; Castellino A; Gotti M; Congiu AG; Cabras MG; Tucci A; Agostinelli C; Ciccone G; Pileri SA; Vitolo U
    Lancet Oncol; 2017 Aug; 18(8):1076-1088. PubMed ID: 28668386
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comorbidity is an independent prognostic factor in patients with advanced-stage diffuse large B-cell lymphoma treated with R-CHOP: a population-based cohort study.
    Wieringa A; Boslooper K; Hoogendoorn M; Joosten P; Beerden T; Storm H; Kibbelaar RE; Veldhuis GJ; van Kamp H; van Rees B; Kluin-Nelemans HC; Veeger NJ; van Roon EN
    Br J Haematol; 2014 May; 165(4):489-96. PubMed ID: 24754632
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and tolerability of rituximab and reduced-dose cyclophosphamide, doxorubicin, vincristine, and prednisolone therapy for elderly patient with diffuse large B-cell lymphoma.
    Kayamori K; Shono K; Onoda M; Yokota A
    Hematology; 2019 Dec; 24(1):52-59. PubMed ID: 30101679
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Outcome of elderly patients with diffuse large B-cell lymphoma treated with R-CHOP: results from the UK NCRI R-CHOP14v21 trial with combined analysis of molecular characteristics with the DSHNHL RICOVER-60 trial.
    Kühnl A; Cunningham D; Counsell N; Hawkes EA; Qian W; Smith P; Chadwick N; Lawrie A; Mouncey P; Jack A; Pocock C; Ardeshna KM; Radford J; McMillan A; Davies J; Turner D; Kruger A; Johnson PW; Gambell J; Rosenwald A; Ott G; Horn H; Ziepert M; Pfreundschuh M; Linch D
    Ann Oncol; 2017 Jul; 28(7):1540-1546. PubMed ID: 28398499
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Attenuated immunochemotherapy regimen (R-miniCHOP) in elderly patients older than 80 years with diffuse large B-cell lymphoma: a multicentre, single-arm, phase 2 trial.
    Peyrade F; Jardin F; Thieblemont C; Thyss A; Emile JF; Castaigne S; Coiffier B; Haioun C; Bologna S; Fitoussi O; Lepeu G; Fruchart C; Bordessoule D; Blanc M; Delarue R; Janvier M; Salles B; André M; Fournier M; Gaulard P; Tilly H;
    Lancet Oncol; 2011 May; 12(5):460-8. PubMed ID: 21482186
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cyclophosphamide, doxorubicin, vincristine, prednisone and rituximab versus epirubicin, cyclophosphamide, vinblastine, prednisone and rituximab for the initial treatment of elderly "fit" patients with diffuse large B-cell lymphoma: results from the ANZINTER3 trial of the Intergruppo Italiano Linfomi.
    Merli F; Luminari S; Rossi G; Mammi C; Marcheselli L; Tucci A; Ilariucci F; Chiappella A; Musso M; Di Rocco A; Stelitano C; Alvarez I; Baldini L; Mazza P; Salvi F; Arcari A; Fragasso A; Gobbi PG; Liberati AM; Federico M
    Leuk Lymphoma; 2012 Apr; 53(4):581-8. PubMed ID: 21895543
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Long-Term Follow-Up of a Phase II Trial of Six Cycles of Dose-Dense R-CHOP-14 for First-Line Treatment of Diffuse Large B-Cell Lymphoma in Young and Elderly Patients.
    González-Barca E; Canales MA; Salar A; Ferrer S; Domingo-Domenech E; Vidal MJ; Grande C; Bargay J; Gardella S; Oriol A; Briones J; García-Frade J; Bello JL; Sánchez-Blanco JJ; Peñalver FJ; Tomás JF; Asensio A; López A; Caballero D;
    Acta Haematol; 2016; 136(2):76-84. PubMed ID: 27188649
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and tolerability of reduced-dose 21-day cycle rituximab and cyclophosphamide, doxorubicin, vincristine and prednisolone therapy for elderly patients with diffuse large B-cell lymphoma.
    Aoki K; Takahashi T; Tabata S; Kurata M; Matsushita A; Nagai K; Ishikawa T
    Leuk Lymphoma; 2013 Nov; 54(11):2441-7. PubMed ID: 23452117
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisolone in patients with newly diagnosed diffuse large B-cell non-Hodgkin lymphoma: a phase 3 comparison of dose intensification with 14-day versus 21-day cycles.
    Cunningham D; Hawkes EA; Jack A; Qian W; Smith P; Mouncey P; Pocock C; Ardeshna KM; Radford JA; McMillan A; Davies J; Turner D; Kruger A; Johnson P; Gambell J; Linch D
    Lancet; 2013 May; 381(9880):1817-26. PubMed ID: 23615461
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Patterns of neutropenia and risk factors for febrile neutropenia of diffuse large B-cell lymphoma patients treated with rituximab-CHOP.
    Choi YW; Jeong SH; Ahn MS; Lee HW; Kang SY; Choi JH; Jin UR; Park JS
    J Korean Med Sci; 2014 Nov; 29(11):1493-500. PubMed ID: 25408580
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Intensified chemotherapy with ACVBP plus rituximab versus standard CHOP plus rituximab for the treatment of diffuse large B-cell lymphoma (LNH03-2B): an open-label randomised phase 3 trial.
    Récher C; Coiffier B; Haioun C; Molina TJ; Fermé C; Casasnovas O; Thiéblemont C; Bosly A; Laurent G; Morschhauser F; Ghesquières H; Jardin F; Bologna S; Fruchart C; Corront B; Gabarre J; Bonnet C; Janvier M; Canioni D; Jais JP; Salles G; Tilly H;
    Lancet; 2011 Nov; 378(9806):1858-67. PubMed ID: 22118442
    [TBL] [Abstract][Full Text] [Related]  

  • 14. CNS International Prognostic Index: A Risk Model for CNS Relapse in Patients With Diffuse Large B-Cell Lymphoma Treated With R-CHOP.
    Schmitz N; Zeynalova S; Nickelsen M; Kansara R; Villa D; Sehn LH; Glass B; Scott DW; Gascoyne RD; Connors JM; Ziepert M; Pfreundschuh M; Loeffler M; Savage KJ
    J Clin Oncol; 2016 Sep; 34(26):3150-6. PubMed ID: 27382100
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Reduced-dose (two-thirds) R-CHOP chemotherapy for elderly patients with non-Hodgkin lymphoma.
    Kikuchi M; Nakasone H; Akahoshi Y; Nakano H; Ugai T; Wada H; Yamasaki R; Sakamoto K; Kawamura K; Ishihara Y; Sato M; Ashizawa M; Terasako-Saito K; Kimura S; Yamazaki R; Kako S; Kanda J; Nishida J; Sekiguchi N; Noto S; Kida M; Hangaishi A; Usuki K; Kanda Y
    J Chemother; 2015 Feb; 27(2):99-105. PubMed ID: 25314911
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Outcomes of very elderly patients with aggressive B-cell non-Hodgkin lymphoma treated with reduced-dose chemotherapy.
    Iioka F; Izumi K; Kamoda Y; Akasaka T; Ohno H
    Int J Clin Oncol; 2016 Jun; 21(3):498-505. PubMed ID: 26463529
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical impact of prognostic nutritional index in diffuse large B cell lymphoma.
    Go SI; Park S; Kang MH; Kim HG; Kim HR; Lee GW
    Ann Hematol; 2019 Feb; 98(2):401-411. PubMed ID: 30413902
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dose-dense rituximab-CHOP compared with standard rituximab-CHOP in elderly patients with diffuse large B-cell lymphoma (the LNH03-6B study): a randomised phase 3 trial.
    Delarue R; Tilly H; Mounier N; Petrella T; Salles G; Thieblemont C; Bologna S; Ghesquières H; Hacini M; Fruchart C; Ysebaert L; Fermé C; Casasnovas O; Van Hoof A; Thyss A; Delmer A; Fitoussi O; Molina TJ; Haioun C; Bosly A
    Lancet Oncol; 2013 May; 14(6):525-33. PubMed ID: 23578722
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Randomized Phase II Study of R-CHOP With or Without Bortezomib in Previously Untreated Patients With Non-Germinal Center B-Cell-Like Diffuse Large B-Cell Lymphoma.
    Leonard JP; Kolibaba KS; Reeves JA; Tulpule A; Flinn IW; Kolevska T; Robles R; Flowers CR; Collins R; DiBella NJ; Papish SW; Venugopal P; Horodner A; Tabatabai A; Hajdenberg J; Park J; Neuwirth R; Mulligan G; Suryanarayan K; Esseltine DL; de Vos S
    J Clin Oncol; 2017 Nov; 35(31):3538-3546. PubMed ID: 28862883
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The Prognostic Impact of Dose-attenuated R-CHOP Therapy for Elderly Patients with Diffuse Large B-cell Lymphoma.
    Tanimura A; Hirai R; Nakamura M; Takeshita M; Hagiwara S; Miwa A
    Intern Med; 2018 Dec; 57(24):3521-3528. PubMed ID: 30101910
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 32.